Clinical Trials · NCT04903509
A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 95
- Start date
- Jun 2021
- Locations
- 1 site, Germany
- Primary endpoint
- Percentage of subjects with drug-related adverse events